DARBID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DARBID (DARBID).
Antimuscarinic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretions.
| Metabolism | Hepatic metabolism (minimal); primarily excreted unchanged in urine. |
| Excretion | Renal: ~50% unchanged; biliary/fecal: ~50% as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 1.5 to 2 hours in adults, requiring frequent dosing for sustained anticholinergic effect. |
| Protein binding | Approximately 20-30% bound to albumin. |
| Volume of Distribution | Approximately 1.0-1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 30-50% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; IM: 15-30 minutes; IV: 5-10 minutes. |
| Duration of Action | Oral: 3-4 hours; IM/IV: 2-3 hours. Clinical effects on gastric secretion may persist up to 6 hours. |
| Molecular Weight | 330.4 |
5 mg orally three times daily, before meals. May be increased to 20 mg per day if necessary.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (eGFR <30 mL/min) due to anticholinergic effects. |
| Liver impairment | No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased anticholinergic effects. |
| Pediatric use | Safety and efficacy not established; not recommended for pediatric use. |
| Geriatric use | Start at 5 mg orally twice daily; increase cautiously due to increased risk of anticholinergic side effects (cognitive impairment, constipation, urinary retention). |
| 1st trimester | Avoid during first trimester due to potential anticholinergic effects and limited safety data; animal studies suggest risk but human data insufficient. |
| 2nd trimester | Use only if clearly needed; may cause fetal tachycardia or other anticholinergic effects; weigh risks vs benefits. |
| 3rd trimester | Avoid near term; may cause neonatal anticholinergic effects (e.g., ileus, tachycardia, sedation). |
Clinical note
Comprehensive clinical and safety monograph for DARBID (DARBID).
| Placental transfer | Crosses placenta in animal studies; human data limited but likely due to low molecular weight and lipophilicity. |
| Breastfeeding | Excreted into breast milk in small amounts; potential for anticholinergic effects in infant (e.g., dry mouth, constipation, irritability); caution is advised, especially in neonates or premature infants; consider alternative agents. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Narrow-angle glaucomaObstructive gastrointestinal disorders (e.g., pyloric stenosis, paralytic ileus)Obstructive uropathy (e.g., urinary retention)Myasthenia gravisSevere ulcerative colitisToxic megacolonHiatal hernia associated with reflux esophagitis
| Precautions | May cause heat prostration in hot environments due to decreased sweating, Caution in glaucoma, pyloric obstruction, prostatic hypertrophy, and hiatal hernia associated with reflux esophagitis, May cause drowsiness or blurred vision |
| Food/Dietary | Avoid alcohol, caffeine, and spicy foods as they may increase gastrointestinal irritation. Take DARBID on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption; however, if gastrointestinal upset occurs, it may be taken with food. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. In first trimester, limited human data; animal studies show increased risk of skeletal anomalies at high doses. Second and third trimesters: potential for decreased fetal heart rate variability and anticholinergic effects (tachycardia, ileus). Avoid in preterm labor due to possible association with neonatal seizures. |
| Fetal Monitoring | Maternal: Monitor heart rate, blood pressure, urinary retention, and mental status. Fetal: Heart rate monitoring for tachycardia; consider ultrasound for growth if used long-term. |
| Fertility Effects | No human studies. Animal data show no major reproductive toxicity. Theoretical anticholinergic effects may alter vaginal secretions or impair uterine contractility during labor. |
| Clinical Pearls | DARBID (isopropamide iodide) is an anticholinergic/antispasmodic agent used primarily for peptic ulcer disease and gastrointestinal hypermotility. Due to its profound antimuscarinic effects, it can cause significant dry mouth, blurred vision, urinary retention, and constipation. Use with caution in patients with glaucoma, prostatic hypertrophy, or myasthenia gravis. Monitor for central nervous system effects, especially in elderly patients. Avoid concurrent use with other anticholinergics to prevent additive toxicity. |
| Patient Advice | Take this medication exactly as prescribed, usually before meals and at bedtime. · Avoid driving or operating heavy machinery until you know how DARBID affects you, as it may cause blurred vision or dizziness. · Drink plenty of fluids and use sugarless candy or gum to relieve dry mouth. · Report any difficulty urinating, severe constipation, or changes in vision to your healthcare provider. · Do not stop taking this medication abruptly without consulting your doctor. |